Intervention not reported
Nicotine patch · adults (aged ≥ 18 years) who smoked cigarettes Components: components of pharmacological and e‐cigarette (EC) interventions for smoking…
The intervention showed no clear difference in nicotine patch (low certainty).
1 finding from 1 review
Intervention not reported
Fast‐acting NRT (nicotine other) · adults (aged ≥ 18 years) who smoked cigarettes Components: components of pharmacological and e‐cigarette (EC) interventions for smoking…
The intervention showed no clear difference in fast‐acting NRT (nicotine other) (low certainty).
1 finding from 1 review
Intervention not reported
Nicotine EC · adults (aged ≥ 18 years) who smoked cigarettes Components: components of pharmacological and e‐cigarette (EC) interventions for smoking…
The intervention showed no clear difference in nicotine EC (low certainty).
1 finding from 1 review
Intervention not reported
Bupropion · adults (aged ≥ 18 years) who smoked cigarettes Components: components of pharmacological and e‐cigarette (EC) interventions for smoking…
The intervention showed no clear difference in bupropion (moderate certainty).
1 finding from 1 review
Intervention not reported
Nortriptyline · adults (aged ≥ 18 years) who smoked cigarettes Components: components of pharmacological and e‐cigarette (EC) interventions for smoking…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvement in vertigo · Ménière’s disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in vertigo · Ménière’s disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · Ménière’s disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvement in vertigo frequency · Ménière’s disease
Intratympanic corticosteroids showed no clear difference in improvement in vertigo frequency compared with placebo/no treatment (low certainty).
2 findings from 1 review
Change in vertigo (global score) · Ménière’s disease
1 finding from 1 review
Change in vertigo frequency · Ménière’s disease
3 findings from 1 review
no estimate extracted
3 studies · 472 participants
Low
no estimate extracted
1 study · 20 participants
Very low
no estimate extracted
1 study · 18 participants
Very low
Serious adverse events · Ménière’s disease
It is very uncertain whether intratympanic corticosteroids changes serious adverse events compared with placebo/no treatment (very low certainty).
1 finding from 1 review
Improvement in vertigo frequency · Ménière’s disease
It is very uncertain whether intratympanic gentamicin changes improvement in vertigo frequency compared with no treatment/placebo (very low certainty).
2 findings from 1 review
Vertigo (global score) at < 3 months · Ménière’s disease
2 findings from 1 review
Vertigo (frequency) · Ménière’s disease
1 finding from 1 review
Serious adverse events · Ménière’s disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvement in vertigo frequency · Ménière’s disease
Positive pressure therapy showed no clear difference in improvement in vertigo frequency compared with placebo (low certainty).
1 finding from 1 review
Change in vertigo (global score) · Ménière’s disease
1 finding from 1 review
Change in vertigo frequency · Ménière’s disease
1 finding from 1 review
Serious adverse events · Ménière’s disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found